High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study

Journal of Translational Medicine

Volumn 8, Issue , 2010, Pages

  Guida, Michele ^a   Cramarossa, Antonio ^a   Fistola, Ettore ^a   Porcelli, Mariangela ^a   Giudice, Giuseppe ^b   Lubello, Katia ^a   Colucci, Giuseppe ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FOTEMUSTINE; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; DACARBAZINE; DRUG DERIVATIVE; NITROSOUREA DERIVATIVE; ORGANOPHOSPHORUS COMPOUND;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; HUMAN; LIVER METASTASIS; LOW DRUG DOSE; LYMPH NODE METASTASIS; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; SKIN METASTASIS; THROMBOCYTOPENIA; VOMITING; METASTASIS; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NITROSOUREA COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS;

EID: 78149239361     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-8-115     Document Type: Article

References (28)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66. 10.3322/canjclin.57.1.43, 17237035.
2. Balch CM, Gershenwald JE, Soong SJ, et al. Final Version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27(36):6199-206. 10.1200/JCO.2009.23.4799, 19917835.
3. Guida M, Latorre A, Mastria A, et al. Subcutaneous recombinant interleukin-2 plus chemotherapy with cisplatin and dacarbazine in metastatic melanoma. Eur J Cancer 1996, 32(4):730-733.
4. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomozed trial of the Darmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999, 17:2745-2761.
5. Ridolfi R, Sileni VC, Guida M, et al. Cisplatin, Dacarbazine with or without Subcutaneous Interleukin-2 and Alfa Interferon Phase III Randomized Trial: Results of an Italian Multicentric Study in Advanced Melanoma Out-Patients. J Clin Oncol 2002, 20(6):1600-07. 10.1200/JCO.20.6.1600, 11896110.
6. Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 2007, 25:5426-5434. 10.1200/JCO.2007.12.0253, 18048825.
7. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000, 18:158-66.
8. Agarwala SS, Kirkwood JM, Gore M, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 2004, 22:2101-2107. 10.1200/JCO.2004.11.044, 15169796.
9. Bafaloukos D, Tsoutson D, Kalofonos H, et al. Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol 2005, 16(6):950-7. 10.1093/annonc/mdi190, 15829494.
10. Jacquillat C, Khayat D, Banzet P, et al. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 1990, 66(9):1873-8. 10.1002/1097-0142(19901101)66:9<1873::AID-CNCR2820660904>3.0.CO;2-5, 2224783.
11. Terheyden P, Becker JC, Kampgen E, et al. Sequential interferon-alpha2b, interleukin-2 and fotemustine for patients with metastatic melanoma. Melanoma Res 2000, 10(5):475-82. 10.1097/00008390-200010000-00010, 11095409.
12. Avril MF, Armadal S, Grab JJ, et al. Fotemustine compared with Dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol. 2004, 22:1118-1125.
13. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA repair gene MGMT and the clinical response of gliomas to alkilating agents. NEJM 2000, 343(19):1350-1354. 10.1056/NEJM200011093431901, 11070098.
14. Gerson SL. Clinical Relevance of MGMT in the Treatment of Cancer. J Clin Oncol 2002, 20(9):2388-2399. 10.1200/JCO.2002.06.110, 11981013.
15. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. NEJM 2005, 352:997-1003. 10.1056/NEJMoa043331, 15758010.
16. Brandes A, Franceschi E, Tosoni A, et al. MGMT Promoter methylation status can predict the incidence and outcomes of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008, 26:2192-2196. 10.1200/JCO.2007.14.8163, 18445844.
17. Hotta T, Saito Y, Fujita H, et al. O6-alkylguanine-DNA alkyltransferase activity of human malignant glioma and its clinical implications. J Neurooncol 1994, 21(2):135-40. 10.1007/BF01052897, 7861189.
18. Vassal G, Boland I, Terrier-Lacombe MJ, et al. Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity. Clin Cancer Res 1998, 4(2):463-8.
19. Belanich M, Pastor M, Randall T, et al. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 1996, 56(4):783-8.
20. Jaeckle KA, Eyre HJ, Townsend JJ, et al. Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol 1998, 16(10):3310-5.
21. D'Incalci M, Taverna P, Erba E, et al. O6-methylguanine and temozolomide can reverse the resistance to chloroethylnitrosoureas of a mouse L1210 leukemia. Anticancer Research 1991, 11:115-122.
22. Gerard B, Aamdal S, Lee SM, et al. Activity and unexpected lung toxicity of the sequential administration of two alkylating agents-dacarbazine and fotemustine-in patients with melanoma. Eur J Cancer 1993, 29A(5):711-9. 10.1016/S0959-8049(05)80352-1, 8471329.
23. Lee SM, Margison GP, Thatcher N, et al. Formation and loss of O6-methyldeoxyguanosine in human leucocyte DNA following sequential DTIC and fotemustine chemotherapy. Br J Cancer 1994, 69(5):853-7. 1968902, 8180013.
24. Gander M, Leyvraz S, Decosterd L, et al. Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours. Cancer Chemother Pharmacol 1994, 34(6):509-14. 10.1007/BF00685663, 7923562.
25. Silvani A, Lamperti E, Gaviali P, et al. Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. J Neurooncol 2008, 87(2):143-51. 10.1007/s11060-007-9427-y, 17576523.
26. Naumann SC, Roos WP, Jöst E, Belohlavek C, Lennerz V, Schmidt CW, Christmann M, Kaina B. Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53. Br J Cancer 2009, 100(2):322-33. 10.1038/sj.bjc.6604856, 2634706, 19127257.
27. Larkin JM, Hughes SA, Beirne DA, et al. A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma. Br J Cancer 2007, 96(1):44-8. 10.1038/sj.bjc.6603503, 2360201, 17146474.
28. Tas F, Camlica H, Topuz E. Temozolomide in combination with fotemustine in patients with metastatic melanoma. Cancer Chemother Pharmacol 2008, 62(2):293-8. 10.1007/s00280-007-0606-5, 17909803.